On May 9, the Senate by a 93-1 vote passed its Food and Drug Administration user fee reauthorization bill (S. 1082). The user fees are paid by prescription drug manufacturers to support the new drug approval process. The bill includes many new drug safety measures. The House is working on its own version of the bill, which reportedly is similar to the Senate bill. The legislation is expected to be on the President’s desk by the end of this summer.